ChemRxiv
These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
2/2
P(V)-platform TEXT.pdf (1015.42 kB)

A P(V)-Platform for Oligonucleotide Synthesis

preprint
submitted on 12.04.2021, 20:53 and posted on 13.04.2021, 13:12 by Phil Baran, Kyle W. Knouse, Yazhong Huang, Shenjie Qiu, wei hao, Natalia Padial, Julien Vantourout, Bin Zheng, Stephen Mercer, Javier Lopez, Rohan Narayan, Richard Olson, Donna Blackmond, Martin Eastgate, Mike Schmidt, Ivar Mcdonald

The early promise of gene-based therapies is currently being realized at an accelerated pace with over 155 active clinical trials for antisense compounds and multiple FDA-approved oligonucleotide therapeutics. Fundamental advances in this area are vital and present an unprecedented opportunity to both address disease states that have been resistant to other common modalities and improve the significant sustainability challenges associated with production of these complex molecules on a commercial scale. The advent of phosphoramidite coupling chemistry and solid-phase synthesis 40 years ago democratized oligonucleotide synthesis to the scientific community, paving the way for many of these stunning developments. The reliability and generality of this approach for the preparation of native phosphate-diesters is attributed to the high reactivity of phosphorus when in the P(III)-oxidation state versus the desired P(V), as it enables rapid P-heteroatom bond formation. However, the growing demand for more diverse phosphorus-based linkages has challenged the limits of this technology. For example, the phosphorothioate (PS) linkage, which stabilizes oligonucleotides towards nuclease cleavage, is universally employed in current oligonucleotide therapeutics but is generally incorporated in racemic form. Stereodefined PS oligonucleotides may have desirable biological and physical properties but are accessed with difficulty using phosphoramidite chemistry. Here we report a flexible and efficient [P(V)]-based platform that can install a wide variety of phosphate linkages at will into oligonucleotides. This approach uses readily accessible reagents and can efficiently install not only stereodefined or racemic thiophosphates, but can install any combination of (S, R or rac)-PS with native phosphodiester (PO2) and phosphorodithioate (PS2) linkages into DNA and other modified nucleotides. Importantly this platform easily accesses this diversity under a standardized coupling protocol with sustainably prepared, stable, P(V) reagents.

Funding

NIGMS GM106210

History

Email Address of Submitting Author

pbaran@scripps.edu

Institution

Scripps Research

Country

United States

ORCID For Submitting Author

0000-0001-9193-9053

Declaration of Conflict of Interest

none

Version Notes

Version 1.0

Exports